1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,170 | 7,870 | 22:37 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 01.04. | Selvita to focus on organic growth in 2026, expects approx. PLN 27 mln savings, higher margins | 3 | PAP |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 253,90 | +2,71 % | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | -3,55 % | Palatin Technologies: Lizenzvereinbarung treibt Umsatz im dritten Quartal an und beflügelt die Aktie | ||
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,420 | +0,71 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 58,30 | -3,48 % | Halozyme Therapeutics, Inc.: Halozyme Reports First Quarter 2026 Results And Reiterates 2026 Financial Guidance | Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026
Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 4,055 | -3,80 % | AbCellera-Aktie vor Zahlen - setzt sich die Rallye weiter fort? | Die AbCellera-Aktie ist am vergangenen Freitag um rund +9% gestiegen und legte nachbörslich nochmals um weitere knapp +5% zu. Damit rücken die heutigen Quartalszahlen zunehmend in den Fokus, da der... ► Artikel lesen | |
| GLOW LIFETECH | 0,027 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Expands Distribution with Two of Canada's Largest Cannabis Retailers, Launches New Product Innovation and Advances National Growth Strategy | Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to provide a commercial update highlighting continued... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 208,40 | +1,16 % | Bio-Rad Laboratories Swings To Q4 Profit |
WASHINGTON (dpa-AFX) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025.... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer | Experienced life sciences leader to drive global commercial strategy and accelerate growth across early- and late-phase biologics programsTUSTIN, Calif., May 11, 2026 /PRNewswire/ -- Avid... ► Artikel lesen | |
| BIOLINERX | 2,400 | +5,26 % | BioLineRx Ltd.; Hemispherian AS: BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) | Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer CenterData... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 4,440 | +32,14 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026
Cash, cash equivalents and short-term investments balance... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 5,080 | +6,99 % | Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates | Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened
Previous open label trial data presented at SIRS 2026 showed no safety or drug-drug... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,340 | -4,10 % | B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target | ||
| COCRYSTAL | 1,110 | -0,89 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen |
Das Unternehmen SELVITA SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 7,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.